From the reports in the media and what people discuss, one is led to believe that CBD (cannabidiol) contains all the medicinal benefits in the cannabis plant while THC (tetrahydrocannabinol) symptomizes everything that is bad about cannabis since it is psychoactive. However, the findings of a recent study may turn this popular belief on its head.
According to a study whose findings appeared in the Scientific Reports Journal, THC seems to have a higher link with the relief of disease symptoms when compared to CBD.
The researchers from the University of New Mexico studied the data provided by medical cannabis users in the U.S. regarding various aspects of the medical cannabis that they consumed. The ReLeaf app allows patients to indicate various things, such as what they are suffering from, what marijuana strains they are consuming, how they are consuming that marijuana and what effects they notice after consuming medical cannabis.
The researchers looked at the data and found that the patients who used marijuana strains that had higher levels of THC when compared to the CBD content reported superior symptom relief unlike those patients whose medical marijuana had low levels of THC and higher levels of CBD.
Sarah See Stith, one of the co-authors of the research commented that their study was important in light of the fact that not enough information is given to patients when they want to try medical cannabis for their conditions.
Stith pointed out that almost all patients get a recommendation from a doctor and are on their own in terms of selecting the products to use. Some of those patients rely on their prior experience when they used to consume recreational marijuana. Others talk to family and friends while some go to the internet to educate themselves about medical cannabis. The staff at medical cannabis dispensaries are often poorly trained, so they cannot be relied upon to give dependable advice on the appropriate medical cannabis products for patients.
Stith thinks that their research findings can help to initiate a discussion and further research into how cannabis works to treat or provide symptomatic relief.
This research is also important because it comes at a time when the U.S., the UN and other international bodies are on the verge of deciding whether to reschedule cannabis or leave it in the most restrictive categories of the national/international treaties controlling narcotic substances.
Youngevity International, Inc. (NASDAQ: YGYI) and Cannabis Strategic Ventures, Inc. (OTC: NUGS) welcome this research and hope that those findings will be considered by those who formulate cannabis policies and regulations in Washington.
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor